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Abstract
Background: African-Americans admitted to U.S. hospitals with community-acquired pneumonia (CAP) are more
likely than Caucasians to experience prolonged hospital length of stay (LOS), possibly due to either differential
treatment decisions or patient characteristics.
Methods: We assessed associations between race and outcomes (Intensive Care Unit [ICU] variables, LOS, 30-day
mortality) for African-American or Caucasian patients over 65 years hospitalized in the Veterans Health Administration
(VHA) with CAP (2002-2007). Patients admitted to the ICU were analyzed separately from those not admitted to the
ICU. VHA patients who died within 30 days of discharge were excluded from all LOS analyses. We used chi-square
and Fisher’s exact statistics to compare dichotomous variables, the Wilcoxon Rank Sum test to compare age by race,
and Cox Proportional Hazards Regression to analyze hospital LOS. We used separate generalized linear mixed-effect
models, with admitting hospital as a random effect, to examine associations between patient race and the receipt of
guideline-concordant antibiotics, ICU admission, use of mechanical ventilation, use of vasopressors, LOS, and 30-day
mortality. We defined statistical significance as a two-tailed p ≤ 0.0001.
Results: Of 40,878 patients, African-Americans (n = 4,936) were less likely to be married and more likely to have a
substance use disorder, neoplastic disease, renal disease, or diabetes compared to Caucasians. African-Americans and
Caucasians were equally likely to receive guideline-concordant antibiotics (92% versus 93%, adjusted OR = 0.99; 95%
CI = 0.81 to 1.20) and experienced similar 30-day mortality when treated in medical wards (adjusted OR = 0.98; 95%
CI = 0.87 to 1.10). African-Americans had a shorter adjusted hospital LOS (adjusted HR = 0.95; 95% CI = 0.92 to 0.98).
When admitted to the ICU, African Americans were as likely as Caucasians to receive guideline-concordant antibiotics
(76% versus 78%, adjusted OR = 0.99; 95% CI = 0.81 to 1.20), but experienced lower 30-day mortality (adjusted
OR = 0.82; 95% CI = 0.68 to 0.99) and shorter hospital LOS (adjusted HR = 0.84; 95% CI = 0.76 to 0.93).
Conclusions: Elderly African-American CAP patients experienced a survival advantage (i.e., lower 30-day mortality)
in the ICU compared to Caucasians and shorter hospital LOS in both medical wards and ICUs, after adjusting for
numerous baseline differences in patient characteristics. There were no racial differences in receipt of guideline-
concordant antibiotic therapies.
Background
Prior studies have documented health disparities
between African-Americans and Caucasians who present
to U.S. hospitals with common infectious diseases [1-4].
Health policies, research initiatives, and targeted
educational campaigns have sought to bridge this quality
chasm [5-7].
In the treatment of community-acquired pneumonia
(CAP), several initial processes of care have been asso-
ciated with improved survival, including the timely
delivery and appropriate selection of antibiotic therapy,
and acquisition of blood cultures prior to initiating
antibiotic therapy [8-11]. These processes have been
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cal practice guidelines, hospital accreditation commis-
sions, and federal agencies [12]; however, whether such
processes of care are performed in an equitable man-
ner for patients of all races is unclear. While some stu-
dies have demonstrated African-American patients are
less likely to receive timely initiation of antibiotic ther-
apy, diagnostic bronchoscopy, smoking cessation coun-
seling, and pneumococcal and influenza vaccinations
[1,3,13,14], the available evidence suggests no differ-
ence between African-Americans and Caucasians in
the likelihood of receiving guideline-concordant anti-
biotic therapy, blood cultures, or assessment of arterial
oxygenation [3,14].
Despite the observed racial disparities in several evi-
dence-based processes of care for CAP, most Veteran
and civilian studies to date have found equal or lower
adjusted mortality rates for African-Americans com-
pared to Caucasians [15-18], with few exceptions [14].
Other evidence suggests African-Americans admitted to
U.S. hospitals with CAP are more likely to experience
prolonged hospital stays [13,19]. It is unclear whether
differences in processes of care, hospital length of stay
(LOS) and mortality are independently associated with
race or due to differences in baseline patient characteris-
tics that vary by race.
The Veterans Health Administration (VHA), the lar-
gest vertically integrated healthcare system in the United
States, has been at the forefront of a national quality
movement to provide high quality and equitable health-
care for all VHA patients. Therefore, we sought to
determine whether there were racial differences in pro-
cesses of care, hospital LOS, or 30-day mortality for
African-American and Caucasian VHA patients with
CAP, after adjusting for baseline differences in patient
characteristics.
Methods
This retrospective, cohort study of hospitalized patients
with CAP is a secondary analysis of data collected as
part of a project to assess the association of treatment
with statins on clinical outcomes (e.g., mortality) of
patients hospitalized with CAP and/or sepsis in the
Department of Veterans Affairs Health Care System
(National Institutes of Health/National Institute of Nur-
sing Research Grant Number R01NR010828). We used
administrative data from the VHA to examine trends in
pneumonia care and mortality. The VHA databases are
repositories of clinical data from more than 150 VHA
hospitals and 850 VHA clinics [20]. The Institutional
Review Board of the University of Texas Health Science
Center at San Antonio and the South Texas Veterans
Health Care System Research and Development com-
mittee approved this study.
Patient Eligibility
We included VHA patients 65 years and older with a
diagnosis of pneumonia in fiscal years 2002-2007. We
used previously validated ICD-9 codes (480.0-483.99 or
485-487) for pneumonia to identify potential cases [21].
We excluded patients with a history of HIV/AIDS
because these patients might be immunocompromised.
We excluded those patients admitted to the hospital or
a nursing home within 90 days prior to the CAP admis-
sion because these would be considered to be health
care associated cases. In addition, we excluded those
without antibiotic therapy within 48 hours of admission
because these might have had hospital acquired pneu-
monia. Finally, we excluded those patients with non-
veteran status or of races other than African-American
or Caucasian.
Baseline Characteristics
We recorded the patient’s age, sex, and marital status
(married versus unmarried) at the time of admission.
We used VHA Priority Group (PG) as a surrogate for
socioeconomic status and disease severity, a previously
validated approach [22-24]. Priority Group is used
within the VHA to determine a Veteran’s eligibility for
health benefits and exemption from copayments for
pharmacy and health care. When assigning the Veterans
to these Priority Groups, the VHA takes into considera-
tion the veteran’s physical and mental health status, ser-
vice history (e.g., Prisoner of War or Purple Heart
recipient), and how related the Veteran’s illness is to
their military service (i.e., “service-connected” disability).
Priority Group 1 veterans are exempt from all copay-
ments; Priority Group 5 veterans are eligible for care
based on their low income. VHA Priority Group 5 is
specifically related to very low income, but a veteran
with a higher priority (lower PG, i.e., 1-4) could also be
low income. In fact, this is often the case. Priority
Group 1 veterans are 50%-100% disabled by a service-
connected condition, and thus may be unable to earn a
good living (if physically disabled) or form supportive
social contacts (if psychiatrically disabled). Catastrophic
disablement (PG 4) is independently associated with low
income in the U.S. veteran population.
We defined 19 comorbid illnesses using ICD-9 codes
in accordance with the Charlson comorbidity scoring
system [25], using ICD-9 codes from prior outpatient
and inpatient care [26]. We defined alcohol abuse or
dependence (ICD-9 codes 291, 303, and 305.0) and
drug abuse or dependence (codes 292, 304, 305.2, and
305.9) [27]. Because lung disease is correlated with
smoking status, we incorporated several approaches to a
smoking indicator, based on prior research with VHA
data [28]. Smoking status recorded in the electronic
medical record is not included in administrative data
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whenever any of the following was found: (a) diagnosis
of nicotine dependence (ICD-9 codes 305.1, V15.82),
(b) outpatient prescription for smoking cessation pro-
ducts (Zyban, Chantix, varenicline, Nicotrol, nicotine
replacement), (c) outpatient visit to smoking cessation
clinic, (d) CPT treatment code for smoking cessation
(99406, 99407). This measure is expected to undercount
patients with a smoking history. VHA enrollees smoke
more than the US population per age- and sex-adjusted
rates [29], but smoking rates also drop with age and
deteriorating health. We also defined organ failure (sin-
gle or multiple) and sepsis based upon the presence of
o n eo rm o r ep r e v i o u s l ye s t a b l i s h e dI C D - 9c o d e sf o r
these conditions [6,7].
Missing data on VHA measures of health services uti-
lization is rare in the administrative data extracts of the
electronic medical record system. However, while VHA
race data have been validated especially for Caucasian
and African-American patients, [30,31] missing data on
race/ethnicity is a persistent problem. In VHA databases
through 2002 (inpatient data) or 2003 (outpatient data),
race/ethnicity was recorded by a clinical or clerical
observer in inpatient records and was rarely missing,
while outpatient records were characterized by higher
rates of missing data. A change in policy was then
effected to capture self-reported race, leading to high
rates of missing data (up to 60% initially). To improve
race/ethnicity data, we used all available years of data.
Missing-on-race has been associated with increased sur-
vival in VHA cohorts defined by outpatient use [32], no
doubt reflecting healthy users’ lack of inpatient services
where race was more likely to be recorded.
Antibiotic Prescribing and Other Pneumonia Processes
of Care
We evaluated antibiotics received within the first 48 hours
of hospital admission per joint American Thoracic Society
(ATS) and Infectious Diseases Society of America (IDSA)
CAP medical practice guidelines [12]. We defined the fol-
lowing antibiotics as guideline-concordant for medical
ward patients: 1) b-lactam plus doxycycline, 2) b-lactam
plus macrolide, or 3) antipneumococcal fluoroquinolone.
We defined guideline-concordant for patients admitted to
the intensive care unit (ICU) as: 1) b-lactam plus macro-
lide, 2) b-lactam plus antipneumococcal fluoroquinolone,
3) antipneumococcal fluoroquinolone plus clindamycin,
4) antipneumococcal fluoroquinolone plus vancomycin, or
5) antipneumococcal fluoroquinolone plus aminoglyco-
side. b-lactams included ampicillin, ampicillin-sulbactam,
cefepime, cefotaxime, cefpodoxime, ceftazidime, ceftriax-
one, ertapenem, imipenem-cilastatin, meropenem, pipera-
cillin-tazobactam, and ticarcillin. Antipneumococcal
fluoroquinolones included ciprofloxacin, gatifloxacin,
gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin,
sparfloxacin, and trovafloxacin. Macrolides included azi-
thromycin, clarithromycin, and erythromycin. Any of
these guideline-concordant therapies could have had
adjunctive linezolid or vancomycin. These antibiotic
recommendations for ward and ICU patients have
remained consistent through several versions of the guide-
lines, including those published by IDSA in 1998, 2003,
and 2007 and those published by ATS in 1995 and 2007.
Thus, no matter which version of the guidelines was fol-
lowed, these patients managed between 2002 and 2007
should have received the therapies in question.
Additional processes of care included ICU admission,
vasopressor use, and mechanical ventilation. We defined
mechanical ventilation using ICD-9A code 96.7,
recorded during an ICU stay. We defined vasopressor
and inotrope use based upon the receipt of any of the
following medications during the hospital stay: dobuta-
mine, dopamine, epinephrine, isoproterenol, metarami-
nol, norepinephrine, phenylephrine, or vasopressin.
Length of Hospital Stay and 30-Day Mortality
We abstracted the admission and discharge dates for
each stay, then defined hospital LOS as the date of dis-
charge minus the date of admission plus one day for the
overall hospitalization. The VHA vital status file pro-
vided date of death to assess 30-day mortality. The
30-day mortality metric includes those patients who
died in the hospital as well as those who died outside
the hospital. We chose this follow-up duration because
previous research demonstrated that 30-day mortality is
primarily due to underlying illness with pneumonia,
whereas 90-day mortality is generally attributable to
other comorbid conditions [33]. Previous research has
demonstrated that this methodology has a sensitivity of
approximately 98% for detecting VHA patients’ deaths
and is as accurate as the National Death Index [34]. In
fact, National Death Index data were incorporated into
the VHA’s ascertainment of death [34].
Statistical analysis
We conducted all analyses using JMP 7.0, SAS 9.2 (SAS
Corp., Cary, NC), and Stata 10 (StataCorp, College
Station, TX). Due to the large sample size, we defined
statistical significance as a two-tailed p ≤ 0.0001. Bivari-
ate statistics (chi-square and Student’s t-test) compared
patient demographics, comorbid conditions, processes of
care, LOS, and 30-day mortality for African-American
and Caucasian patients with CAP. When assessing study
endpoints, patients admitted to the ICU were analyzed
separately from those not admitted to the ICU. VHA
patients who died within 30 days of discharge were
excluded from all LOS analyses. This was done because
patients who died rapidly experienced abbreviated
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stay for those very severe patients is artificially short
because the patients expired before they could complete
an entire episode of care. This approach (i.e., censoring
those patients who died from the LOS analyses) is con-
sistent with numerous other peer reviewed publications
[35-38].
We used chi-square and Fisher’s exact statistics to
compare dichotomous variables, the Wilcoxon Rank
Sum test to compare age by race, and Cox Proportional
Hazards Regression to analyze hospital LOS. We used
separate generalized linear mixed-effect models, with
admitting hospital as a random effect, to examine asso-
ciations between patient race and the receipt of guide-
line-concordant antibiotics, ICU admission, use of
mechanical ventilation, use of vasopressors, hospital
LOS, and 30-day mortality. Hazard ratios, odds ratios,
and 95% confidence intervals were calculated from the
generalized linear mixed-effects models. Covariates
included all 18 variables listed in Table 1 plus a hospi-
tal-level variable. Hazard ratios were reported for hospi-
tal LOS; whereas, odds ratios were reported for
everything else. For LOS, hazard ratios <1 indicate
shorter lengths of stay; whereas, hazard ratios >1 indi-
cate longer lengths of stay.
The 18 variables listed in Table 1 were considered
ap r i o r ito be clinically important, and we included
them as covariates in each of the multivariable models.
The bulk of these variables were chosen because they
were key components of well-validated scoring systems
that predict patient mortality among pneumonia
patients (e.g., age, sex, heart failure, cerebrovascular dis-
ease, liver disease, renal disease, neoplastic disease)
[39,40]. Other variables were included because we
Table 1 Comparison of baseline patient characteristics for African-American and Caucasian patients admitted to VHA
Hospitals with CAP (n = 40,878)*
Total African-Americans Caucasians
Patient Characteristics (n = 40,878) (n = 4,936) (n = 35,942) P-value
Demographics
Age (yrs), median (interquartile range) 78 (72-83) 77 (72-82) 78 (72-83) 0.005
Male, % 98% 99% 98% <0.0001
Married, % 53% 43% 55% <0.0001
Priority group (PG), % <0.0001
PG 1 18% 13% 19% –
PG 2 5% 4% 5% –
PG 3 9% 7% 9% –
PG 4 15% 21% 14% –
PG 5 43% 48% 43% –
PG 6 <1% <1% <1% –
PG 7 3% 2% 3% –
PG 8 6% 4% 6% –
Comorbid conditions, %
Myocardial infarction 5% 4% 5% <0.0001
Heart failure 22% 19% 22% <0.0001
Cerebrovascular disease 16% 16% 16% 0.2
Chronic obstructive pulmonary disease 51% 39% 53% <0.0001
Liver disease <1% <1% 1% 0.2
Diabetes 30% 32% 30% <0.0001
Renal disease 10% 16% 10% <0.0001
Neoplastic disease 21% 24% 20% <0.0001
Tobacco use 37% 32% 37% <0.0001
Alcohol abuse or dependence 3% 4% 3% 0.0002
Substance abuse or dependence 3% 4% 3% <0.0001
Organ failure and sepsis, %
†
Any organ failure 25% 27% 25% 0.0014
Multiple organ failure 6% 6% 5% 0.0061
Sepsis 4% 5% 4% 0.0009
*These results reflect the bivariate statistical tests (chi-square and Wilcoxon Rank Sum tests).
†These variables were coded during hospitalization, but were not necessarily known at admission; therefore, they could represent baseline disease severity or
complications.
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hospital length of stay (e.g., marital status, priority
group [a surrogate for socioeconomic status], chronic
obstructive pulmonary disease, tobacco use, alcohol
abuse or dependence, substance abuse or dependence,
any organ failure, multiple organ failure, or sepsis).
Results
Overall, 4,936 African-American and 35,942 Caucasian
VHA patients met all eligibility criteria (n = 40,878).
The study population had a median (interquartile range)
age of 78 (72-83) years; 98% were male and 53% were
married. History of tobacco dependence (37%), chronic
obstructive pulmonary disease (51%), diabetes (30%),
heart failure (22%), neoplastic disease (21%), and cere-
brovascular disease (16%) were common. One-quarter
(25%) had organ failure while 4% had sepsis, and 12%
were admitted to the ICU at some point during
hospitalization.
Baseline Characteristics by Patient Race
As shown in Table 1, compared to Caucasians, a greater
proportion of African-American VHA patients were sin-
g l e( 5 7 %v e r s u s4 5 % ) ,h a dah i g h e rp r e v a l e n c eo fs u b -
stance abuse (4% versus 3%), neoplastic disease (24%
versus 20%), renal disease (16% versus 10%), and diabetes
(32% versus 30%). In contrast, Caucasian VHA patients
were more likely to have a history of myocardial infarc-
tion (5% versus 4%), heart failure (22% versus 19%), and
chronic obstructive pulmonary disease (53% versus 39%).
Socioeconomic status, as measured by priority group,
also differed significantly between the two cohorts.
Antibiotic Prescribing and Intensive Care Measures
by Race
Medical Wards
Among VHA patients managed in the medical wards,
African-American and Caucasian patients were equally
likely to receive guideline-concordant antibiotic therapy
in bivariate (92% versus 93%) and multivariable
(adjusted OR = 0.99; 95% CI = 0.81 to 1.20) analyses
(Tables 2 and 3). Guideline-concordant antibiotic
prescribing rates increased over time, from 90-91% in
2002 to 94-95% in 2007 (Figure 1). This possibly reflects
greater awareness and appreciation for the benefits asso-
ciated with the CAP guidelines in the ward setting.
Intensive Care Units
African-American and Caucasian VHA patients experi-
enced similar rates of admission to the ICU (12% ver-
sus 13%). Of those patients admitted to the ICU,
African-American and Caucasian patients were equally
likely to receive guideline-concordant antibiotic ther-
apy in bivariate (76% versus 78%, p = 0.3) and multi-
variable (adjusted OR = 0.99; 95% CI = 0.81 to 1.20)
analyses (Tables 4 and 5). Antibiotic prescribing rates
did not differ significantly between Black and White
patients admitted to the ICU. Guideline-concordant
prescribing was less common in the ICU as compared
to the ward, and there was no discernible increase in
guideline-concordant prescribing for the latter years
studied (Figure 2). This possibly reflects a lack of con-
sensus regarding the most appropriate therapies for
CAP patients admitted to the ICU. Use of vasopressors
(adjusted OR = 1.27; 95% CI = 1.04 to 1.55) and
mechanical ventilation (adjusted OR = 1.40; 95% CI =
1.15 to 1.70) was more common for African-Americans
than Caucasians.
30-day Mortality and Hospital Length of Stay by
Patient Race
Medical Wards
African-American and Caucasian patients managed on
medical wards experienced similar adjusted 30-day mor-
tality (adjusted OR = 0.98; 95% CI = 0.87 to 1.10). Afri-
can-American patients had a shorter adjusted hospital
LOS (adjusted HR = 0.95; 95% CI = 0.92 to 0.98)
(Tables 2 and 3).
Intensive Care Units
African-American patients admitted to the VHA ICUs
experienced lesser adjusted 30-day mortality (adjusted
OR = 0.82; 95% CI = 0.68 to 0.99) and shorter adjusted
hospital LOS (adjusted HR = 0.84; 95% CI = 0.76 to
0.93) compared to Caucasian patients admitted to VHA
ICUs (Tables 4 and 5).
Table 2 Antibiotic prescribing, Hospital LOS, and 30-day mortality for African-American and Caucasian VHA patients
with CAP managed in the medical wards (non-ICU patients) (n = 35,706)*
Total African-Americans Caucasians P-value
Guideline-concordant antibiotics
† 93% 92% 93% 0.0221
LOS, median (interquartile range)
‡ 4 (3-7) 4 (3-7) 4 (3-7) 0.0015
30-day mortality, % 8% 9% 8% 0.0563
LOS = length of stay.
*These results reflect the bivariate statistical tests (chi-square and Wilcoxon Rank Sum tests).
†Guideline-concordant antibiotics were those consistent with 2007 American Thoracic Society/Infectious Diseases Society of America community-acquired
pneumonia guidelines[12]. See study methods for more information.
‡VHA patients who died within 30 days of hospital discharge were excluded from all LOS analyses.
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Our principle finding was that African-Americans
admitted to VHA hospitals for CAP experienced similar
or lower adjusted 30-day mortality compared to Cauca-
sians admitted to VHA hospitals for CAP. Given the
size, scope, and inclusion of important covariates, this
study is an important addition to the literature. Our
analysis of over 40,000 patients from more than 150
VHA hospitals from across the U.S. is one of the largest
of its kind. Our study provides a contemporary assess-
ment of guideline-concordant prescribing in both VHA
hospital wards and ICUs. Our analysis incorporates
patient and hospital characteristics that could be predic-
tive of patient outcome, including patient medical his-
tory, social history, socioeconomic status, disease
complications, and treatment f a c i l i t y .I ns od o i n g ,t h i s
study provides one of the most robust assessments of
health disparities in the U.S. Veteran and civilian litera-
ture. The absence of a disadvantage for African-Ameri-
cans suggests African-American and Caucasian patients
admitted to VHA hospitals have equal access to care
and receive inpatient treatment of similar quality. Equal
access to care is a central goal of health care, and this
study brings merit to the initiatives of clinicians striving
to care for all patients with the highest standards.
African-American patients admitted to VHA ICUs
experienced a survival advantage (i.e., lower 30-day mor-
tality) compared to Caucasian patients admitted to VHA
ICUs. While this survival advantage has been documen-
ted in other studies [15-18], there is no clear explana-
tion for it. Possibly, the Caucasian patients admitted to
VHA ICUs were more severely ill than the African-
American patients admitted to VHA ICUs; however, this
seems unlikely given that both cohorts had similar rates
of ICU admission and vasopressor use and mechanical
ventilation were more common among African-Ameri-
cans. While our study lacked some of the clinical vari-
ables required to apply prognostic scoring tools (e.g.,
PSI, CURB-65, and APACHE-II) [39,40], we included
several key covariates including demographic factors
(i.e., age, gender) and all five comorbidities (i.e., neoplas-
tic disease, liver disease, heart failure, cerebrovascular
disease, and renal disease) used in the PSI score. Thus,
our study was well suited to capture/control for the
known effects of comorbid illness on mortality for CAP
patients. Nevertheless, it is possible that the difference
in mortality was due to some unmeasured comorbidity
(i.e., receipt of active chemotherapy, immunosuppressive
illness, etc) that may have been more prevalent or more
problematic for Caucasian patients admitted to the ICU.
The difference in mortality could also be due to differ-
ences in advanced directives between the two cohorts.
Table 3 Multivariable analyses for antibiotic prescribing,
Hospital LOS, and 30-day mortality for African-American
and Caucasian VHA patients with CAP managed in the
medical wards (non-ICU patients) (n = 35,706)*
Dependent variable HR/OR (95% CI)
Guideline-concordant antibiotics
† 0.99, 0.81-1.20
LOS
‡ 0.95, 0.92-0.98
30-day mortality 0.98, 0.87-1.10
LOS = length of stay.
*Hazard ratios, odds ratios, and 95% confidence intervals were calculated
from the generalized linear mixed-effects models. Covariates included all
18 variables listed in Table 1 plus a hospital-level variable. Hazard ratios were
reported for hospital LOS; whereas, odds ratios were reported for everything
else. For LOS, hazard ratios <1 indicate shorter lengths of stay; whereas,
hazard ratios >1 indicate longer lengths of stay.
†Guideline-concordant antibiotics were those consistent with 2007 American
Thoracic Society/Infectious Diseases Society of America community-acquired
pneumonia guidelines[12]. See study methods for more information.
‡VHA patients who died within 30 days of hospital discharge were excluded
from all LOS analyses.
Figure 1 Annual guideline-concordant prescribing for African-American and Caucasian VHA patients with CAP managed in the
medical wards (non-ICU patients)*. *The numbers in the figure represent the crude (unadjusted) guideline-concordant antibiotic prescribing
rates.
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likely to have “do not intubate” or “do not resuscitate”
orders on file as compared to African-American patients
[ 4 1 ] .I ft h i si si n d e e dt r u e ,then patients with advanced
directives may receive less aggressive therapy. This may
partially explain why the African-American patients in
our study had higher rates of vasopressor use and
mechanical ventilation than the Caucasian patients.
We acknowledge the growing body of literature on
frailty [42-44], and recognize the mortality difference
might be attributable to differences in frailty between
African-American and Caucasian patients admitted to
VHA ICUs. The Caucasian patients could be more frail
due to a variety of comorbid conditions (i.e., osteoporo-
sis, weight loss or low BMI, cellulitis or decubitus ulcers,
fluid electrolyte imbalances, anemia, age >80, syncope,
nursing home residence). Likewise, a growing body of
literature suggests the importance of functional status,
particularly among nursing home patients admitted with
pneumonia [45-51]. Poor functional status may contri-
bute to patient mortality and an increased risk of drug
Table 4 Antibiotic prescribing, intensive care measures, Hospital LOS, and 30-day mortality for African-American and
Caucasian VHA patients with CAP admitted to the intensive care units (ICU patients) (n = 5,172)*
Total African-Americans Caucasians P-value
Guideline-concordant antibiotics
† 77% 76% 78% 0.3383
Intensive care measures, %
Intensive care unit admission 13% 12% 13% 0.0023
Vasopressors 26% 32% 26% 0.0005
Mechanical ventilation 42% 48% 41% 0.0005
LOS, median (interquartile range)
‡ 12 (7-23) 13 (7-31) 11 (7-22) <0.0001
30-day mortality, % 31% 29% 31% 0.2806
LOS = length of stay.
*These results reflect the bivariate statistical tests (chi-square and Wilcoxon Rank Sum tests).
†Guideline-concordant antibiotics were those consistent with 2007 American Thoracic Society/Infectious Diseases Society of America community-acquired
pneumonia guidelines[12]. See study methods for more information.
‡VHA patients who died within 30 days of hospital discharge were excluded from all LOS analyses.
Table 5 Multivariable analyses for antibiotic prescribing,
intensive care measures, Hospital LOS, and 30-day
mortality for African-American and Caucasian VHA
patients with CAP admitted to the intensive care units
(ICU patients) (n = 5,172)*
Dependent variable HR/OR (95% CI)
Guideline-concordant antibiotics
† 0.99, 0.81-1.20
Intensive care measures
Vasopressors 1.27, 1.04-1.55
Mechanical ventilation 1.40, 1.15-1.70
LOS
‡ 0.84, 0.76-0.93
30-day mortality 0.82, 0.68-0.99
LOS = length of stay.
*Hazard ratios, odds ratios, and 95% confidence intervals were calculated
from the generalized linear mixed-effects models. Covariates included all 18
variables listed in Table 1 plus a hospital-level variable. Hazard ratios were
reported for hospital LOS; whereas, odds ratios were reported for everything
else. For LOS, hazard ratios <1 indicate shorter lengths of stay; whereas,
hazard ratios >1 indicate longer lengths of stay.
†Guideline-concordant antibiotics were those consistent with 2007 American
Thoracic Society/Infectious Diseases Society of America community-acquired
pneumonia guidelines[12]. See study methods for more information.
‡VHA patients who died within 30 days of hospital discharge were excluded
from all LOS analyses.
Figure 2 Annual guideline-concordant prescribing for African-American and Caucasian VHA patients with CAP admitted to the intensive
care units (ICU patients)*. *The numbers in the figure represent the crude (unadjusted) guideline-concordant antibiotic prescribing rates.
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sures of frailty or functional status.
In addition to differences in mortality, Caucasian
patients in our study remained hospitalized longer than
African-American patients. This was the case for both
the ward and ICU subgroups. This finding contradicts
previous studies reporting longer stays for African-
Americans admitted to U.S. hospitals with CAP [13,19].
The previous findings were observed in civilian hospitals
and Bennett et al point out that the correlations
reported were almost entirely attributable to differences
in insurance status and hospital characteristics between
racial groups. We did account for priority group and
admitting hospital in our multivariable, generalized
linear mixed-effect models. We also accounted for 18
other baseline patient characteristics, including several
that were significantly different between the two
cohorts: marital status, myocardial infarction, heart fail-
ure, chronic obstructive pulmonary disease, diabetes,
renal disease, neoplastic disease, tobacco use, and sub-
stance abuse. Nevertheless, it is possible that observed
differences in hospital LOS were due to other unmea-
sured variables.
When differences in hospital LOS are observed
between two groups, it is important to consider if the
group with the shorter hospital LOS experiences any
clinical detriment for having been discharged sooner.
This could be evaluated by considering hospital read-
mission rates or mortality post hospital discharge. We
analyzed 30-day mortality and found that African-
American and Caucasian patients discharged from VHA
hospitals experienced similar 30-day mortality; we can
therefore conclude that the African-American patients
admitted to VHA ICUs did not experience any addi-
tional clinical detriment for having been discharged
from the hospital sooner than their Caucasian
counterparts.
African-American and Caucasian VHA patients in our
study were equally likely to receive guideline-concordant
antibiotic therapy in ward and ICU settings, a finding
consistent with a previous study [3]. This finding is
paramount since numerous studies have previously cor-
related guideline-concordant prescribing with improved
patient survival [10,52,53]. The guidelines recommend
slightly different antibiotic regimens in ward and ICU
settings, so it is not surprising that the guideline adher-
ence rates differ somewhat in these two settings. In
addition, the recommendations for ward patients have
been validated to a greater extent than the recommen-
dations for ICU patients [38,54].
We did not evaluate individual guideline-concordant
therapies, nor did we attempt to correlate certain
guideline-concordant therapies with patient race. We
recognize that selection from among the various
guideline-concordant therapies must be somewhat cus-
tomized on the basis of patient history, risk factors for
multi-drug resistant pathogens, prior antibiotic expo-
sure, and patient comorbidities. National pneumonia
guidelines encourage prescribers to consider these
things when selecting empiric antibiotic therapies [12].
Since African-American and Caucasian patients dif-
fered on several baseline characteristics and comorbid-
ities, we would expect to see slight variations in
prescribing within the guideline-concordant therapies.
A few of those divergent baseline characteristics are
described here along with possible implications for
empiric antibiotic therapy.
African-American VHA patients were more likely to
have a history of substance abuse or dependence, neo-
plastic disease, renal disease, and diabetes. In contrast,
Caucasian VHA patients were more likely to use
tobacco, or have a history of heart failure or chronic
obstructive pulmonary disease. These observed differ-
ences in comorbidities are consistent with other studies
in various infectious diseases, which demonstrate that
African-Americans often present to hospitals with more
comorbidities compared to Caucasians [3,7,19,55].
Patients with diabetes or renal disease may be less likely
to receive fluoroquinolone antibiotics to avoid accumu-
lation in renal disease or a perpetuation of glycemic
abnormalities. On the other hand, if patients with renal
disease receive antibiotics that are excreted by the kid-
neys (i.e., fluoroquinolones or b-lactams), then they get
greater antibiotic exposure, and possibly better efficacy,
from the same dose due to their renal compromise.
This may impact hospital LOS as recent data suggest
certain guideline-supported therapies are associated with
shorter hospital stays [56].
Past studies have demonstrated that African-American
patients are less likely to receive timely antibiotic ther-
apy and diagnostic bronchoscopy [1,3,13]. We did not
capture or evaluate antibiotic timing in our study. We
also did not evaluate bronchoscopy; however, we did
quantify and compare use of vasopressors and mechani-
cal ventilation between African-American and Caucasian
cohorts. We found that African-Americans were more
likely to receive these intensive therapies as compared
to Caucasians. We did not evaluate acquisition of blood
cultures or oxygenation assessment; two process
measures previously found to be similar for African-
American and Caucasian VHA patients [3].
Our study has limitations that are inherent to all ret-
rospective cohort studies. The results attributed to one
explanatory variable could be the result of some unmea-
sured variable. Any relationships uncovered cannot be
definitively considered causative.
The VHA patients in this study are not necessarily
representative of all U.S. patients or even all U.S.
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Page 8 of 11veterans [57]. The VHA caters to the most disadvan-
taged veterans and VHA patients are, on average, poorer
and sicker than U.S. residents or U.S. veterans [57].
Those with highly service-connected disabilities also
receive entry into the VHA system preferentially, and
service-connected disability of 50% or more (VA Priority
Group 1) garners care without copayments. Lower
priority groups (PG 1-6) generally incur copayments for
medication prescription, and the lowest priority VA
patients (PG 7-8) also have copayments for care. Also, it
is certainly possible that African-Americans managed in
the VHA system are different from African-Americans
managed in other systems.
Additionally, this study was potentially limited by the
fact that the investigators were unable to fully exclude
VHA patients with healthcare-associated pneumonia
(HCAP); however, the stringent exclusion criteria should
have minimized these patients. For instance, VHA
patients admitted to the hospital or a nursing home
within the 90 days prior to the index admission for CAP
were excluded. Prior studies have demonstrated that
these two exclusions account for a large proportion
of HCAP patients [58,59]. As with any study with non-
prospective data collection, we are unable to fully exclude
the possibility of missing data. However, VA data have
been demonstrated to have excellent validity and reliabi-
lity [60]. Finally, while errors occur in all databases, as
well as in chart data, the VHA databases have been
shown to be extraordinarily valid with respect to coding
of diagnoses especially on inpatient encounters [60].
Conclusions
Elderly African-American CAP patients experienced a
survival advantage (i.e., lower 30-day mortality) in the
ICU compared to Caucasians and shorter hospital LOS
in both medical wards and ICUs, after adjusting for
numerous baseline differences in patient characteristics.
There were no racial differences in receipt of guideline-
concordant antibiotic therapies.
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